H.R. 1418 · 118th Congress · House

Animal Drug and Animal Generic Drug User Fee Amendments of 2023

In Congress· Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 210.
Introduced
Mar 7, 23
Passed House
Jul 17, 23
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Animal Drug and Animal Generic Drug User Fee Amendments of 2023

This bill reauthorizes the Food and Drug Administration (FDA) to collect fees for brand-name and generic animal drug applications through FY2028. It also makes related updates to fee calculations and FDA reporting requirements.

The bill also (1) provides for a specific fee for requests to establish generic investigational new animal drug files and requires other application fees to be adjusted accordingly; (2) authorizes the FDA to remove species from the definition of major species (currently horses, dogs, cats, cattle, pigs, chickens, and turkeys); and (3) provides statutory authority for the FDA to report on its progress supporting antimicrobial stewardship in veterinary settings (i.e., supporting responsible use of antimicrobial drugs for animals to slow the development of drug-resistant bacteria).

Animal drugs are drugs that are intended for animals other than humans (e.g., pets and livestock). Animal drugs must be approved by the FDA before they may be offered on the commercial market. The FDA is authorized to collect fees for animal drug applications in order to support its regulatory activities; this authority currently expires at the end of FY2023.

Previous Versions

07Jun 9, 2023

Animal Drug and Animal Generic Drug User Fee Amendments of 2023

This bill reauthorizes the Food and Drug Administration (FDA) to collect fees for brand-name and generic animal drug applications through FY2028. It also makes related updates to fee calculations and FDA reporting requirements.

The bill also (1) provides for a specific fee for requests to establish generic investigational new animal drug files and requires other application fees to be adjusted accordingly; (2) authorizes the FDA to remove species from the definition of major species (currently horses, dogs, cats, cattle, pigs, chickens, and turkeys); and (3) provides statutory authority for FDA to report on its progress supporting antimicrobial stewardship in veterinary settings (i.e., supporting responsible use of antimicrobial drugs for animals to slow the development of drug-resistant bacteria).

Animal drugs are drugs that are intended for animals other than humans (e.g., pets and livestock). Animal drugs must be approved by the FDA before they may be offered on the commercial market. The FDA is authorized to collect fees for animal drug applications in order to support its regulatory activities; this authority currently expires at the end of FY2023.

00Mar 7, 2023

Animal Drug User Fee Amendments of 2023

This bill reauthorizes the Food and Drug Administration (FDA) to collect fees for brand-name and generic animal drug applications through FY2028. It also makes related updates to fee calculations and FDA reporting requirements.

The bill also provides for a specific fee for requests to establish generic investigational new animal drug files and requires other application fees to be adjusted accordingly.

Animal drugs are drugs that are intended for animals other than humans (e.g., pets and livestock). Animal drugs must be approved by the FDA before they may be offered on the commercial market. The FDA is authorized to collect fees for animal drug applications in order to support its regulatory activities; this authority currently expires at the end of FY2023.

Action Timeline

19
  1. SEP 20, 2023Calendars

    Read twice

    Placed on Senate Legislative Calendar under General Orders. Calendar No. 210.

  2. JUL 18, 2023IntroReferral

    Received in the Senate.

  3. JUL 17, 2023Floor

    Mr

    Bilirakis moved to suspend the rules and pass the bill, as amended.

  4. JUL 17, 2023Floor

    Considered under suspension of the rules

    (consideration: CR H3620-3624)

    3620Yea
    3624Nay
    0NV
  5. JUL 17, 2023Floor

    DEBATE - The House proceeded with forty minutes of debate on H.R. 1418.

  6. JUL 17, 2023Floor

    Passed/agreed to in House

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H3620-3623)

    3620Yea
    3623Nay
    0NV
  7. JUL 17, 2023Floor

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H3620-3623)

    3620Yea
    3623Nay
    0NV
  8. JUL 17, 2023Floor

    Motion to reconsider laid on the table Agreed to without objection.

  9. JUN 09, 2023Committee

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-104.

    118Yea
    104Nay
    0NV
  10. JUN 09, 2023Committee

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-104.

    118Yea
    104Nay
    0NV
  11. JUN 09, 2023Calendars

    Placed on the Union Calendar, Calendar No. 80.

  12. MAY 24, 2023Committee

    Committee Consideration and Mark-up Session Held.

  13. MAY 24, 2023Committee

    Ordered to be Reported (Amended) by the Yeas and Nays: 49 - 0.

    49Yea
    0Nay
    0NV
  14. MAY 17, 2023Committee

    Subcommittee Consideration and Mark-up Session Held.

  15. MAY 17, 2023Committee

    Forwarded by Subcommittee to Full Committee in the Nature of a Substitute (Amended) by the Yeas and Nays: 29 - 0 .

    29Yea
    0Nay
    0NV
  16. MAR 17, 2023Committee

    Referred to the Subcommittee on Health.

  17. MAR 07, 2023IntroReferral

    Introduced in House

  18. MAR 07, 2023IntroReferral

    Introduced in House

  19. MAR 07, 2023IntroReferral

    Referred to the House Committee on Energy and Commerce.

Committees

6

Energy and Commerce Committee

hsif00

Referred: Jun 9, 2023

Active

Energy and Commerce Committee

hsif00

Referred: May 24, 2023

Active

Health Subcommittee

hsif14

Referred: May 17, 2023

Active

Health Subcommittee

hsif14

Referred: May 17, 2023

Active

Health Subcommittee

hsif14

Referred: Mar 17, 2023

Active

Energy and Commerce Committee

hsif00

Referred: Mar 7, 2023

Active